Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0SR5L
|
|||
| Drug Name |
PMID27215781-Compound-19
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
ARENA PHARMACEUTICALS, INC. BLACKBURN, Anthony C. HAN, Sangdon JONES, Robert M. MONTALBAN, Anthony Garrido PAL, Biman B. RUETER, Jaimie Karyn
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 2 (CB2) | Target Info | Agonist | [1] |
| Target's Patent Info | Cannabinoid receptor 2 (CB2) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.